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eplerenone reduces renal interstitial fibrosis after
long-term cyclosporine treatment in rat:
antagonizing cyclosporine nephrotoxicity
Finn Thomsen Nielsen1,2*, Boye L Jensen1, Pernille BL Hansen1, Niels Marcussen3 and Peter Bie1Abstract
Background: Chronic cyclosporine-(CsA)-mediated loss of kidney function is a major clinical problem in organ
transplantation. We hypothesized that the mineralocorticoid receptor antagonist eplerenone (EPL) prevents chronic
CsA-induced renal interstitial volume increase, tubule loss, and functional impairment in a rat model.
Methods: Sprague–Dawley rats received CsA alone (15 mg/kg/d p.o.), CsA and EPL (approximately 100 mg/kg/day
p.o.) or vehicle (control) for 12 weeks. At 11 weeks, chronic indwelling arterial and venous catheters were implanted
for continuous measurements of arterial blood pressure (BP) and GFR (inulin clearance) in conscious, freely moving
animals. Plasma was sampled for analysis and kidney tissue was fixed for quantitative stereological analyses.
Results: Compared to controls, CsA-treatment reduced relative tubular volume (0.73±0.03 vs. 0.85±0.01, p<0.05)
and increased relative interstitial volume (0.080±0.004 vs. 0.045±0.003, p<0.05); EPL attenuated these changes
(0.82±0.02, p<0.05, and 0.060±0.006, p<0.05, respectively). CsA-treated rats had more sclerotic glomeruli and a
higher degree of vascular depositions in arterioles; both were significantly reduced in CsA+EPL-treated animals. CsA
increased BP and reduced body weight gain and GFR. In CsA+EPL rats, weight gain, GFR and BP at rest (daytime)
were normalized; however, BP during activity (night) remained elevated. Plasma sodium and potassium
concentrations, kidney-to-body weight ratios and CsA whole blood concentration were similar in CsA and CsA+EPL
rats.
Conclusions: It is concluded that in the chronic cyclosporine rat nephropathy model, EPL reduces renal tissue
injury, hypofiltration, hypertension, and growth impairment. MR antagonists should be tested for their
renoprotective potential in patients treated with calcineurin inhibitors.
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The calcineurin inhibitor cyclosporine A (CsA) is a
powerful macrolide immunosuppressive agent widely
used after organ transplantation. The calcineurin in-
hibitors exert major nephrotoxic effects that involve
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reproduction in any medium, provided the orarterioles as well as a pro-fibrotic effect in the chronic
phase [1,2]. Many treatment options have been examined
with the purpose of countering these adverse effects, but
until recently there have been no single pharmacological
approach to prevent the gradual decline in renal function
and the progressive renal fibrosis occurring during CsA
treatment. There is solid evidence to indicate that aldos-
terone aggravates the CsA-induced nephrotoxicity [3-8]
and consequently, that mineralocorticoid receptor (MR)
blockade might have a preventive effect. In short-term
animal studies (up to 21 days) the MR-antagonist spirono-
lactone slowed the progression of renal dysfunction andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment in rats [3-7]. The more selective MR antagonist
eplerenone (EPL) antagonized the deterioration of renal
function and blood pressure (BP) increase occurring in the
early stage (21 days of treatment) of CsA-treated rats [8].
With respect to adverse effects, EPL has a clinical profile
superior to that of spironolactone [9]. Preventing the CsA-
mediated renal fibrosis and loss of nephrons during chronic
treatment is a major clinical challenge. However, in animal
model studies appropriate quantitative techniques have
been applied only for periods of 2–3 weeks. The present
study was undertaken to test the hypothesis that the select-
ive MR-antagonist EPL protects against renal epithelial cell
loss and interstitial fibrosis in a long-term model (12 weeks)
of CsA nephropathy. To assess the tissue volume fraction
occupied by interstitium and tubules, a quantitative un-
biased stereological method was applied to analyse fixed
kidney sections from the CsA-induced rat nephropathy
model. Arterial and venous catheters were implanted for
continuous recordings of BP, determination of glomerular
filtration rate GFR, and blood sampling in conscious,
unstressed animals. Components of the renin-angiotensin
system, CsA and, electrolytes were measured in plasma.
This study reports results of MR-inhibition in CsA-
treated rats in which renal fibrosis, interstitial expansion,
and loss of tubular mass were reduced, renal function
preserved, and BP lowered in a 12 week model.Methods
Experimental animals
Inbred, male Sprague–Dawley rats (Mol:SPRD) from
Harlan Scandinavia (Harlan, Alleroed, Denmark) initially
weighing 180–240 g were used. The rats had free access
to tap water and a wet mash standard non-salt-reduced
diet (AltrominW Standard 1320 with 0.2% sodium, Lage,
Germany) and were housed in air-conditioned rooms at
a 12h light and 12h dark (LD 12:12) cycle. The investiga-
tion was performed according to “Guide for the Care
and Use of Laboratory Animal” published by the US
National Institute of Health, and the experimental proto-
col was approved by the Danish Animal Experiments In-
spectorate (j.no. 2007/561-1389).Drug preparation and treatment protocol
The rats were treated by a daily gavage with CsA
(Sandimmune NeoralW, Novartis Pharma AG, Basel,
Switzerland) for the CsA (n=11) and CsA+EPL (n=11)
groups or vehicle (castor oil) only (n=11) for 12 weeks.
The CsA dose was 15 mg/kg/d; the doses were adjusted
in steps with the weight increase of the individual rat.
For administration of EPL, tablets of 50 mg (InspraW,
Pharmacia Ltd., Northumberland, England) were crushed
and added to the diet: 1.2 mg/g dry food approximating adaily dose of 100 mg/kg body weight [10]. The non-EPL
treatment groups received a similar diet without EPL.
During the treatment period, six rats were excluded
due to aspiration after CsA-administration. Two rats in
the CsA-alone treatment group were excluded due to
general weakness and dehydration; both of them showed
signs of pneumonia at autopsy.
Catheters in artery and vein
Chronic indwelling catheters were placed in the femoral
vessels for arterial blood sampling, measurements of
arterial BP, and intravenous infusions [11]. Animals were
anaesthetised as described previously [8]. Following the
operation the catheters were attached to a swivel
enabling the rats to move freely irrespective of BP
measurements, arterial blood sampling, and venous
infusions.
Blood pressure measurements and clearance studies
Two days after surgery, the arterial catheter was con-
nected to a BP transducer linked to an amplifier (BLPR
and BP1, World Precision Instruments, Hertfordshire,
United Kingdom) and a computer running custom
designed soft-ware (LabVIEW Real-TimeW, version 7 Ex-
press, National InstrumentsTM, Dublin, Ireland) for con-
tinuous recording of BP and heart rate. BP was
measured on-line during 96 hours. The venous catheter
was connected to an infusion pump delivering inulin
(Polyfructosan S, LaevosanW, Petrone Group, Napoli,
Italy) 25% w/vol at a rate of 4 μl/kg/min. After four days
it was assumed that steady state was obtained, i.e., the
rate of excretion was constant and equal to the rate of
infusion. Therefore, inulin clearance was calculated as
infusion rate divided by plasma concentration. Arterial
blood samples were centrifuged immediately and plasma
separated and stored at -80°C. Separate whole blood
samples were drawn for analysis of CsA concentrations.
Analysis
Whole blood CsA concentrations (trough levels) were
measured after 12 weeks of treatment in samples
collected 22–26 hours after the last administration of
CsA. Analyses were performed with a radioimmunoassay
kit (TDx/TDxFLx; Abbott Laboratories, Abbott Park, IL,
USA).
Inulin concentrations in plasma were analysed by the di-
phenylamine method [12] modified for microanalysis. By
addition of inulinase, inulin is hydrolysed under propor-
tionally consumption of nicotinamide adenine dinucleotide
(NADH). NADH was determined by spectrophotometry at
340 nm (VersamaxWMicro plate reader, Molecular Devices
Corporation, Sunnyvale, CA, USA).
Plasma concentrations of sodium and potassium ions
were determined by flame photometry (ILS 943,
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was measured by the antibody trapping method of
Poulsen and Jorgensen [13], and aldosterone was
measured by a commercial radioimmunoassay kit (Coat-
A-CountW Aldosterone, Diagnostic Products Corporation,
Los Angeles, CA, USA).Morphology
Under anaesthesia (fentanyl and fluanisone at doses of
236 μg/kg and 7.5 mg/kg, respectively (HypnormW,
VetaPharma, Sherburn-in-Elmet, Leeds, UK), midazolam
3.75 mg/kg (DormicumW, Roche Pharmaceuticals, Basel,
Switzerland) administered intraperitoneally, and N2O/O2
50/50%) the right kidney was removed, weighed and
quick frozen while the left kidney was perfusion-fixed
with formaldehyde 4% for 5 min, weighed, divided into
slices of 1 mm, and stored in formaldehyde. Subse-
quently, every second of the 1 mm slices were embedded
in paraffin, cut at 3 μm in thickness, and stained with
PAS and Masson-Trichrome. Using a light microscope
with motorized stage and the CAST-grid analysis soft-
ware, the volume fractions of tubules and the volume
fraction of the interstitial space in the cortex were
estimated by point counting in eighty systematically ran-
domly sampled areas from each individual animal
[14,15]. In addition, semiquantitative grading (0 to 3) of
hyaline vacuolisation in tubules and of vascular hyaline
depositions in arterioles was performed.Western immunoblotting
Rat renal cortex tissue was homogenized in sucrose/
imidazole buffer (0.3 M sucrose, 25 mM imidazole, 1
mM EDTA, pH 7.2. Before use supplemented with pro-
tease inhibitors: 0.4 M pefablock, 2.1 mM leupeptin and
phosphatase inhibitors: 1 mM Na-ortho-vanadate, 0.2 M
NaF and 0.082 μg/μL okadaic acid). Protein was quanti-
fied by the Bradford method. For western blotting 10 μg
of protein was run in a SDS-PAGE gel. Each sample was
added reducing agent (NuPAGE Sample Reducing agent,
Invitrogen) and sample buffer (NuPAGE LDS Sample
buffer, Invitrogen) and denatured for 5 min at 95°C be-
fore running. Proteins were transferred to an acti-
vated 0.45-μm pore-size Immobilon-P PVDF-membrane
(Millipore) in the blotting system (XCell SureLock Mini-
Cell system, Invitrogen). Membranes were blocked with
5% nonfat milk in TBST for one hour before incubation
with primary antibody. Primary antibodies used were –
α-SMA (ab5694, Abcam, 1:1.000), E-cadherin (610181,
BD Biosciences, 1:20.000) and pAkt/PKB (Santa Cruz
Biotechnology, 1:2.000). The antigen-antibody complex
was visualized by horseradish peroxidase-conjugated sec-
ondary antibodies (1:2.000, Dako, Denmark).Statistics
Analysis of variance (ANOVA) was applied for compari-
son of data collected from more than two groups.
In case of significance by ANOVA, group-to-group
comparisons were done with Dunnett's Multiple Com-
parison Test. Values are given as mean ± SEM. A p value
below 5% was considered statistically significant.
Results
Effect of eplerenone on kidney morphological parameters
following 12 weeks cyclosporine treatment
Focal tubular atrophy, interstitial inflammation and fibrosis,
and more sclerotic glomeruli were observed in response to
CsA (Figure 1A). Hyaline tubular casts and tubular dilata-
tion as well as hyaline deposition in arterioles, mainly
located close to the glomeruli, were seen in most of the
animals treated with CsA; a semiquantitative score of 2 vs.
0.5 (p<0.05) (Figure 1B, Table 1). Stereological quantitation
of kidney tissue showed that CsA-treated rat kidneys
displayed a significantly lower volume fraction of tubules
(Figure 1C) and a significantly expanded volume fraction of
renal interstitium compared to controls (Figure 1D). The
CsA-induced changes in the relative tubular and interstitial
volumes were all significantly attenuated by EPL treatment
(Figure 1A, 1C, 1D) (p<0.05), and also the score for hyaline
vacuolisation in tubules and of vascular depositions in
arterioles were significantly attenuated by EPL treatment
(p<0.05) (Figure 1B, Table 1).
Effect of eplerenone on somatic growth
Cyclosporine A (CsA) whole blood concentrations in the
CsA-alone treatment group and the combination therapy
group were statistically indistinguishable (Table 2). Over
the twelve weeks of treatment, the body weight in the CsA
group increased significantly less than that of the control
rats (p<0.002, Table 2). During combination treatment, the
body weight increased at a rate similar to that of the control
rats (Table 2). Kidney weight/body weight ratio did not vary
significantly between groups (Table 2).
Effect of eplerenone on kidney function and plasma
electrolytes after 12 weeks of cyclosporine treatment
CsA alone decreased GFR by 56%; concomitant EPL treat-
ment abolished the decrease in GFR (p<0.05, Figure 2).
Compared to controls, plasma potassium and plasma so-
dium did not change during CsA treatment (Table 2).
Plasma aldosterone was significantly higher in the EPL-
treated group than in controls and in the CsA-only treat-
ment group (p<0.05) (Table 2). Plasma renin was higher in
the combination treatment group compared to controls
while the animals treated with CsA alone did not
have plasma renin levels significantly different from
controls (Table 2).
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Figure 1 A. Renal cortex of rats after 12 weeks of treatment with cyclosporine A, cyclosporine A in combination with eplerenone, or
controls receiving vehicle only. In a CsA treated rat, the tissue shows diffuse interstitial inflammation, atrophic tubules, and a sclerotic
glomerulus. CsA+EPL treated rat kidney section appears normal and not different from control-vehicle with respect to morphology of the
glomerulus, arterioles, and tubules. PAS x100. B. Section of renal cortex of rats after 12 weeks of treatment with cyclosporine A, cyclosporine A in
combination with eplerenone, or controls receiving vehicle only. In a CsA treated rat there is massive hyaline arteriolar vacuolization whereas after
CsA and EPL treatment the hyaline arteriolar vacuolization appears less pronounced and widespread and not very different from a control-vehicle
rat. PAS x200. C. Stereological quantitation of the volume fraction (Vv) of tubules in renal cortex of rats receiving 12 weeks of treatment with
cyclosporine A (n=8) or cyclosporine A in combination with eplerenone (n=9) compared to vehicle- controls (n=11). Values were obtained by a
blinded cast-grid analysis counting eighty frames from each individual rat. PAS x100. CsA: Cyclosporine A. EPL: Eplerenone. *) p<0.05 when
compared to the control group. D. Volume fractions (Vv) of the interstitium in renal cortex of rats receiving 12 weeks of treatment with
cyclosporine A (n=8) or cyclosporine A in combination with eplerenone (n=9) compared to controls (n=11). CsA: Cyclosporine A. EPL:
Eplerenone. *) p<0.05 when compared to the control group.
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cyclosporine treatment
CsA treatment resulted in significantly higher mean ar-
terial BP daytime as well as night time, when compared
to controls (p<0.05, Figure 3B); a typical 24-hourrecording is shown in Figure 3A. Interestingly, the com-
bination therapy reduced this effect significantly during
daytime; during night hours, the BP tended to be similar
to the CsA treated animals (Figure 3B); this tendency is
also visible in the 24-hour curves (Figure 3A).
Table 1 Semiquantitative scoring of hyaline vacuolization
in tubules and of vascular depositions in arterioles in
renal cortex of rats treated for 12 weeks with
cyclosporine A with/without eplerenone
Variable Units CsA CsA + EPL Controls
N 8 9 11
Semiquantitative grading Score 0-3 2* (1–2) 1± (0–2) 0.5± (0–1)
CsA: cyclosporine A. EPL: eplerenone.
Results are shown as median values and range.
*: p<0.05 when compared to the control group.
PASx100.
CsA CsA+EPL Controls
0.0
0.2
0.4
0.6
0.8
*
GFR (ml/min/gKW)
Figure 2 Glomerular filtration rate as measured by inulin
clearance after 12 weeks of treatment with cyclosporine A,
cyclosporine A in combination with eplerenone or vehicle-
controls. CsA: Cyclosporine A. EPL: Eplerenone. BW: Body weight.
KW: Kidney weight. GFR: Glomerular filtration rate as measured by
inulin clearance. *) p<0.05 when compared to the control group.
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Western immunoblotting for the epithelial marker
E-cadherin in kidney tissue homogenates showed a mod-
est, but significant decrease in abundance in response to
CsA (Figure 4), while the mesenchymal cell marker
alpha smooth muscle actin was elevated by CsA treat-
ment. EPL did not alter CsA-induced change in alpha
smooth muscle actin while the decrease in E-cadherin
was attenuated (Figure 4). Abundance of phosphorylated
protein kinase B/Akt, a target of activated MR, was not
altered by CsA (Figure 4).
Discussion
The present long-term CsA-nephrotoxicity study shows
a significant protective effect of the MR blocker EPL on
loss of renal tubules, extracellular matrix expansion,
elevated BP, decreased GFR, and impaired somatic
growth. Quantitative morphological analysis of renal tis-
sue revealed a preventive effect of EPL on the progres-
sive development of fibrosis and tubular loss relevant for
the clinical setting [4-6,8]. In short-term studies, renal
function, as measured by GFR, was reduced in CsA-
treated animals when compared to controls, but partial-
ly preserved in animals in which the CsA treatment
was combined with MR-receptor inhibitors [3-8]. The
present study indicates that the protection of GFRTable 2 Animal growth and blood values during 12 weeks of
Variables Units
N
Increase in BW grams/week
Body weight g
Kidney weight (right) g
Kidney weight (total)/BW ratio mg/g
P potassium mmol/l
P sodium mmol/l
P renin mIU/l
P aldosterone pg/ml
B cyclosporine ng/ml
B: Whole blood. BW: Body weight. CsA: cyclosporine A. EPL: eplerenone. P: plasma.
Results are shown as mean values +/− SEM.
*: p<0.05 when compared to the control group.by EPL is maintained during long-term treatment.
Hyperkalemia was not a major challenge in the present
or previous studies. A major target for MR is protein
kinase B/Akt. The present data did not support an effect
of EPL to prevent phosphorylation (activation) of protein
kinase B/Akt, as no major changes in renal tissue abun-
dance of phopho-Akt were detected. EPL also did not
alter tissue abundance of the mesenchymal cell marker
alpha-smooth muscle cell actin, while the CsA-mediated
decrease in E-cadherin was attenuated by EPL corrobor-
ating a tubular protective effect by EPL. This observation
indicates that the apparent interstitial expansion might
be secondary to disappearance of tubules rather that pri-
mary fibrotic expansion/proliferation. The improved
weight gain in EPL-treated rats, compared to the CsA
alone treated animals, could be due to direct effects on
appetite by EPL or – more likely – by antagonizing the
adverse effects of CsA or by reduction of the uraemia
and malnutrition arising from the nephrotoxicity. The
drop-out rate was low; two cases of fatal infections were
seen in the CsA treatment group; that was the case intreatment with cyclosporine A with/without eplerenone
CsA CsA + EPL Controls
8 9 11
13.4*± 5.2 22.2± 4.0 23.0± 5.0
372* ± 14 461 ± 16 486 ± 13
1.4 ± 0.2 1.7 ± 0.2 1.6 ± 0.2
7.8 ± 1.6 7.4 ± 1.2 6.6 ± 0.8
5.1 ± 0.9 5.1 ± 0.4 4.8 ± 0.3
140.9 ± 4.9 141.7 ± 4.6 143.0 ± 3.7
7.4 ± 1.9 12.7 ± 3.9* 4.0 ± 1.1
65 ± 14 493 ± 135* 57 ± 17
3423 ± 549 2346 ± 254 0
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Figure 3 A. Intra-arterial blood pressure measurement by indwelling chronic catheter during 24 hours after 12 weeks of treatment
with cyclosporine A, cyclosporine A in combination with eplerenone or vehicle-control. Each rat had blood pressure and pulse measured
every five minutes during a 96 hours period as the results continually were collected. Mean intra-arterial blood pressure measured continually by
chronic indwelling catheters in conscious rats receiving either cyclosporine (CsA), CsA+eplerenone (CsA+EPL), or vehicle (controls). Values showed
in 5 minutes intervals for a 24 hours period given as absolute numbers for a single rat from each treatment group. B. Intra-arterially mean blood
pressure in conscious rats after 12 weeks of treatment with cyclosporine A, cyclosporine A in combination with eplerenone, or controls. Mean
intra-arterial blood pressure measured continually by chronic indwelling catheters in conscious rats receiving cyclosporine (CsA), CsA+eplerenone
(CsA+EPL), or vehicle (controls). Resting hours: 06:00–18:00; activity hours: 18:00–06:00. Data are means ± SEM. * p<0.05 compared to controls
CsA: Cyclosporine A. EPL: Eplerenone. Mean BP: Mean intra-arterial blood pressure.
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were seen in the control rats; this difference was not sig-
nificant and therefore not a significant confounder.
In absolute terms, mean BP levels in all groups were
relatively high which could be related to the social
deprivation or the surgical history [16]. However, mean
BP in the CsA treatment group was significantly higher
than controls in concordance with earlier studies, while
the group receiving combination therapy with CsA+EPL
had a 24-hour mean BP value that was significantly
lower than the CsA treated group. The mean BP in the
combination treatment group was not different from
that of controls. A subsequent analysis of diurnal
variations showed that BP reduction occurred during the
resting period (Figure 3A and Figure 3B). During the ac-
tivity period, rats have an up to ten-fold higher plasma
aldosterone level compared to resting day-time periods[17], and data support the notion of diurnal regulation
of aldosterone-renal ENaC expression and sodium bal-
ance with lower activity during sleep. EPL appears to re-
store the normal dipping pattern disturbed by CsA. On
the other hand, this diurnal fluctuation may account for
the variation in EPL efficacy towards BP reduction (night
time activation; superimposed stimulation of renin
secretion by CsA and further stimulation of aldosterone
secretion by EPL [18]). Another explanation of the circa-
dian variation of the EPL effect could be a higher sympa-
thetic tone seen during activity hours at night not
significantly influenced by EPL. The beneficial effect
of EPL on CsA-induced tissue injury could be
accomplished through a direct effect on tubular epithe-
lial target cells or indirectly by the antihypertensive ef-
fect. Clinical and experimental animal studies, however,
have demonstrated that normalization of BP per se does
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Figure 4 Analysis of phospho-Akt/PKB (~60 kDa), E-cadherin
(~120 kDa), and alpha smooth muscle actin (not shown)
protein abundances in renal tissue homogenates from rats
receiving 12 weeks of treatment with cyclosporine A,
cyclosporine A in combination with eplerenone and vehicle-
controls (n=6-8 per condition). Bar graphs show mean
densitometry values from immunoblotting experiments for each
condition compared to vehicle control. The same control samples
were run on each gel together with CsA-treated and combinated
treated rat tissue homogenates. Densitometry values were set to
100% in controls. CsA: Cyclosporine A. EPL: Eplerenone. SMC:
Smooth muscle cells. Values are given as relative changes compared
to controls.
* p<0.05 when compared to the control group.
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treatment [4,8,19,20]. In accord with a direct effect,
calcineurin is co-localized with MR in the distal
aldosterone-sensitive segment of the nephron [21].
CsA has been shown to stimulate renin secretion
directly [22], and EPL is likely to further stimulate renin
indirectly through the increased sodium excretion. In ac-
cordance with this we found that plasma renin was
higher in the combination treatment group compared to
controls (Table 2).
The single, daily dosage of CsA (15 mg/kg/d) was
rather high compared to the human clinical setting;
however, it was chosen based on results from earlier
dose–response studies in this particular rat strain where
this dose provided full immunosuppressive effect [1].
Identical whole blood CsA concentrations were obtained
in the two groups as in previous nephrotoxicity studies
[1,2,23], and at levels similar to peak whole blood
concentrations in patients (~2-3 micromol/L). The for-
mula and dosing of EPL was established previously to be
effective in rats [10].
We did not use a reduced salt diet as we wanted to ana-
lyse a situation resembling as close as possible the clinical
setting. In addition, in an earlier short-term study we
found a preventive effect of MR-inhibition without using
a salt-reduced diet [8].
Clinically, the progressive tissue injury after CsA is a
major challenge and although the acute and short-term
effects can be prevented to some degree, e.g. by angio-
tensin converting enzyme inhibitors [4], calcium channel
antagonists [19], or angiotensin II receptor blockade
[20], these treatments do not improve the long-term
clinical outcome. Angiotensin II has been suggested to
be responsible for up-regulation of fibrogenic pathways
[24], but the observation that MR blockade protects
against tissue injury suggests that aldosterone is also
involved [25]. The beneficial effect of EPL appears to be
a “class effect” since spironolactone has also been shown
to prevent CsA nephrotoxicity [3-7] and it appears to be
a specific effect not related to BP lowering.
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This long-term experimental animal study of CsA-
nephrotoxicity demonstrates a significant protective ac-
tion of an MR antagonist on tissue injury (reduced renal
fibrosis, interstitial expansion, and loss of tubular mass),
GFR, BP and the ability to thrive, and suggests that MR
antagonists should be tested for their renoprotective
actions in clinical settings.
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